Organogenesis(ORGO)

Focus: Organogenesis is a public regenerative medicine and biologics company focused on wound care, orthopedic, and tissue regeneration therapies. With $433M in FY2025 revenue, they operate as a mid-cap biotech with a portfolio of FDA-approved and clinical-stage products.

Regenerative Medicine Biologics Wound Care Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Organogenesis

AI assessmentNot Hiring

No open roles listed right now. Follow Organogenesis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

8 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$433M

Key Products

Apligraf

Venous leg ulcers, epidermolysis bullosa, diabetic foot ulcers

Peak

Flagship product with Phase 3/4 programs across multiple chronic wound indications, demonstrating broad clinical utility and revenue generation.

Dermagraft

Diabetic foot ulcers, venous leg ulcers

Help build intelligence for Organogenesis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status (NASDAQ: ORGO) with established $433M revenue base provides stability and equity upside potential versus private startups
Deep portfolio of 38 active clinical programs across regenerative medicine, wound care, and orthopedics offers diverse technical career paths and learning opportunities
Recent clinical wins (170-patient DFU study cleared key goal in April 2026) and upcoming regulatory catalysts (knee OA therapy moving toward FDA filing) signal momentum in pipeline progression

Watch Out For

Minimal hiring activity (only 4 open roles documented) suggests limited near-term growth or expansion plans, indicating constrained career advancement opportunities
Revenue declined 4% YoY ($451M in FY2024 to $433M in FY2025) with net income drop of 69% ($16M to $5M), signaling profitability pressures despite public status
Only 10% R&D intensity is below industry average for biotech, indicating lower investment in innovation relative to revenue and potentially limited resources for scientific advancement

Generated by Claude from Organogenesis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Core commercial product with two Phase 3 programs underway, key to company's wound care market position.

Gintuit

Gingival recession, edentulous alveolar ridge

Growth

Periodontal regeneration asset with Phase 3 trial in gingival recession, targeting high-value dental market.

Pipeline & Clinical Trials

VCT-01

Wounds

N/A

Clinical Trials (1)

NCT01292122Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds

N/A

Affinity

Venous Leg Ulcer

N/A

Clinical Trials (1)

NCT04901013Clinical Study Of Affinity Versus SOC In The Management Of VLUs

N/A

NuShield

Tendon Injuries

N/A

Clinical Trials (2)

NCT03828916NuShield in Surgical Peroneal Tendon Repair

N/A

NCT07510412Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

N/A

One or two level lumbar interbody fusion surgery

Degenerative Disc Disease

N/A

Clinical Trials (1)

NCT02808234Study of Nucel for One and Two Level Lumbar Interbody Fusion

N/A

Affinity Allograft

Diabetic Foot Ulcers

N/A

Clinical Trials (1)

NCT02880592Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers

N/A

PuraPly™ Antimicrobial Wound Matrix

Partial Thickness Wound

N/A

Clinical Trials (1)

NCT03286452The RESPOND Registry

N/A

NuCel with Autograft

Intervertebral Disc Disease

N/A

Gintuit

Gingival Recession

N/A

Clinical Trials (1)

NCT01547962A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

N/A

PuraPly™ Antimicrobial Wound Matrix

Pressure Ulcer

N/A

Clinical Trials (1)

NCT03070938PuraPly™ Antimicrobial Wound Matrix and Wound Management

N/A

NuShield

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT03855514Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

N/A

Standard of Care

Diabetic Foot Ulcer

N/A

ReNu

Osteochondral Defect

N/A

Clinical Trials (1)

NCT03036878ReNu™ Marrow Stimulation Augmentation

N/A

PuraPly™ Antimicrobial Wound Matrix

Pressure Ulcers

N/A

Clinical Trials (1)

NCT03070925Prospective PuraPly™ AM Case Series Study

N/A

PuraPly® Antimicrobial Wound Matrix

Chronic Pressure Ulcers

N/A

Clinical Trials (1)

NCT03502824PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

N/A

NuTech Affinity™ Membrane

Chondral Lesions

N/A

Clinical Trials (1)

NCT02837484NuTech Affinity™ for the Treatment of Chondral Defects

N/A

CelTx™

Gingival Recession

N/A

Clinical Trials (1)

NCT01134081Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts

N/A

Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System

Diabetic Foot Ulcer

N/A

Affinity human amniotic membrane

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT03205436Affinity Prospective Diabetic Foot Trial Crossover Group

N/A

NuShield

Foot Ulcer, Diabetic

N/A

Clinical Trials (1)

NCT02461641NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers

N/A

ReNu Injection

Fasciitis, Plantar

N/A

ReNu™ Injection

Osteoarthritis, Hip

N/A

Clinical Trials (1)

NCT03063099ReNu™ Injection to Treat Hip Osteoarthritis Study

N/A

Knee injection

Osteoarthritis

N/A

Clinical Trials (1)

NCT02318511An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis

N/A

Gintuit

Edentulous Alveolar Ridge

PHASE_1_2

Clinical Trials (1)

NCT01929954Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

Phase 1/2

CelTx

Gingival Recession

PHASE_1_2

Clinical Trials (1)

NCT00679081A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage

Phase 1/2

Apligraf

Keloid

PHASE_1_2

Clinical Trials (1)

NCT00587587A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

Phase 1/2

Dermagraft

Diabetic Foot Ulcer

PHASE_3

Clinical Trials (1)

NCT01181440Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers

Phase 3

Gintuit

Gingival Recession

PHASE_3

Clinical Trials (1)

NCT00587834Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration

Phase 3

Bi-layered cell therapy

Diabetic Foot

PHASE_3

Clinical Trials (1)

NCT00512538Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

Phase 3

Dermagraft

Venous Leg Ulcer

PHASE_3

Clinical Trials (1)

NCT00909870Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

Phase 3

Amniotic Suspension Allograft

Knee Osteoarthritis

PHASE_3

Clinical Trials (1)

NCT06000410A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

Phase 3

Apligraf

Epidermolysis Bullosa, Junctional

PHASE_3

Clinical Trials (1)

NCT00587223Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Phase 3

Amniotic Suspension Allograft

Knee Osteoarthritis

PHASE_3

Clinical Trials (1)

NCT04636229Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

Phase 3

Dermagraft

Diabetic Foot Ulcer

PHASE_3

Clinical Trials (1)

NCT01181453Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers

Phase 3

Apligraf

Epidermolysis Bullosa

PHASE_4

Clinical Trials (1)

NCT01619670A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa

Phase 4

Apligraf

Venous Ulcer

PHASE_4

Clinical Trials (1)

NCT01327937A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

Phase 4

Apligraf

Venous Leg Ulcers

PHASE_4

Clinical Trials (1)

NCT02011724A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®

Phase 4

Apligraf

Varicose Ulcer

PHASE_4

Clinical Trials (1)

NCT00648674A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 34 clinical trials

Top TAs: Dermatology

Publications: 27 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Dermatology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$433M4%

R&D Spend

$44M(10%)12%

Net Income

$5M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

A deep dive into the essential steps of robotic-assisted laparoscopic hysterectomy for trainees.

Journal of gynecology obstetrics and human reproduction

2026

PMID:41702492

Human iPSC cardiomyocyte patch transplantation modifies extracellular matrix and fibroblast behavior after myocardial infarction.

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Organogenesis(ORGO)

About Organogenesis

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Recent News · Organogenesis(10)

Open Jobs (0)

Financials (FY2025)

Research Publications(10)